BioLargo, Inc. develops and commercializes sustainable technologies across cleantech, environmental engineering, water treatment and life sciences. Company updates commonly cover its Aqueous Electrostatic Concentrator, a PFAS treatment technology designed to remove and collect per- and polyfluoroalkyl substances from liquid streams, as well as engineering services and project work in water, wastewater, remediation and minerals processing.
BioLargo news also follows subsidiary activity, including Clyra Medical Technologies and its FDA-cleared wound care products based on Copper-Iodine Complex Technology, distribution partnerships for ViaCLYR, investor communications, annual operating results, and commercialization updates across medical, environmental and battery-related business lines.
BioLargo, Inc. (OTCQB:BLGO) reported a quarterly revenue record of approximately $900,000 for Q1 2022, marking a 60% increase from Q1 2021. The company's subsidiaries, ONM Environmental and BioLargo Engineering, contributed $550,000 and $350,000 to this revenue, respectively. Additionally, BioLargo Engineering has been awarded a feasibility contract for a waste-to-energy conversion plant in South America, potentially worth over $500 million. This project could engage BioLargo for the next four years, supporting its growth strategy in sustainable technology.
BioLargo, Inc. (OTCQB:BLGO) will host an investor webcast and conference call on April 4, 2022, at 1:30 pm PT to discuss year-end financial results and recent commercial milestones. The public can participate through a webcast or teleconference. The event aims to enhance investor relations by providing insights into the company’s performance and future plans. A replay will be available until April 18, 2022, for the teleconference, and until April 4, 2023, for the webcast. BioLargo specializes in innovative technologies for environmental challenges.
BioLargo, Inc. (OTCQB:BLGO) has filed its Annual Report on Form 10-K for 2021, showcasing significant financial and commercial advancements. The company reported a 4% revenue increase to $2.53 million, despite a 14% year-over-year revenue decline in Q4. Total debt decreased from $2.9 million to $681,000, while net loss fell by 29% to $6.9 million. Key developments include partnerships for PFAS treatment technology and a successful market introduction of new products. An investor webcast will be held on April 4, 2022, to discuss further details and future growth opportunities.
BioLargo, Inc. (OTCQB:BLGO) announced progress on three key growth initiatives:
- The Minimal Liquid Discharge Water Treatment System successfully passed factory acceptance testing, demonstrating over 98% contaminant removal.
- The Aqueous Electrostatic Concentrator (AEC) for PFAS removal is advancing with ongoing studies and potential field trials.
- Collaborations with Ikigai Marketing Works are showing promise in the rollout of a new pet odor control product, exceeding initial expectations.
The company emphasizes its commitment to innovation and sustainability.
BioLargo, Inc. (OTCQB:BLGO) announced that its Aqueous Electrostatic Concentrator (AEC) successfully eliminated multiple PFAS compounds from municipal water in Southern California. PFAS, harmful chemicals linked to serious health concerns and persistent in the environment, are facing increased regulatory scrutiny. The AEC technology has shown the ability to reduce PFAS levels below quantification limits, confirming its efficacy in providing safe drinking water. This advancement is crucial as BioLargo prepares for commercial trials and sales, positioning itself as a leader in PFAS removal solutions.
BioLargo, Inc. (OTCQB:BLGO) is advancing the commercialization of its innovative wastewater treatment technology, the minimal liquid discharge system, developed for Garratt-Callahan. The company will use a full-scale prototype to treat simulated and actual industrial wastewater, aimed at optimizing performance before sales to Garratt-Callahan customers begin. This technology is designed to reduce wastewater volume and disposal costs, while also enhancing environmental sustainability. BioLargo emphasizes its commitment to sustainable solutions and innovation in wastewater treatment.
BioLargo, Inc. (OTCQB:BLGO) has entered into a manufacturer's representative agreement with ICS Group, focusing on the sale of its innovative water treatment technologies. This partnership marks a significant step in expanding BioLargo's commercial network. ICS Group will promote BioLargo's proprietary solutions, including the Advanced Oxidation System and the Aqueous Electrostatic Concentrator, designed for wastewater treatment and PFAS contamination removal. The deal also includes BioLargo's PFAS Testing Program and CupriDyne Clean odor control product.
BioLargo, Inc. (OTCQB:BLGO) has received a 'go decision' from its partner Ikigai Holdings to expand television advertising for its new pet odor control product, 'POOPH'. The decision follows successful test marketing results, indicating strong potential for the product's commercial success. Ikigai CEO Jane Pak highlighted positive early feedback and plans for an extensive marketing campaign post-Christmas. BioLargo CEO Dennis P. Calvert mentioned the partnership could generate significant revenue, with Ikigai managing product rollout and distribution.
BioLargo, Inc. (OTCQB:BLGO) has filed its Quarterly Report for Q3 2021, revealing a 7% increase in consolidated revenue to $712,000, largely driven by a 73% rise in the engineering division. The company's net loss decreased to $1.3 million, down from $2.1 million the previous year due to reduced interest expenses. Key progress includes successful PFAS treatment tests with prospective clients, completion of a prototype for Garratt-Callahan, and promising pilot results for the AOS technology, solidifying its position for future growth.
BioLargo, Inc. (OTCQB:BLGO) will host an investor webcast on November 17, 2021, at 8:00 AM PST / 11:00 AM EST, to discuss its financial results and recent commercial milestones. The event is public and will include a Q&A session. Investors can access the live stream and replay through the company's website. BioLargo specializes in sustainable environmental technologies, holding numerous patents and executing various projects, while also emphasizing partnerships and innovative solutions to environmental challenges.